Summary
Asensus Surgical, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery (MIS) in the United States, Europe, and Asia. It digitizes the interface between the surgeon and the patient to pioneer a new era of Performance-Guided surgery by unlocking clinical intelligence for surgeons to enable consistently superior outcomes and a new standard of surgery. The company's products include Senhance Surgical system, a multi-port robotic surgery system that allows up to four arms to control robotic instruments and a camera for laparoscopic procedures. Its products also comprise instruments and other products, including 3mm diameter instruments, 3mm and 5mm hooks, and articulating instruments; and Senhance ultrasonic system, an advanced energy device to deliver controlled energy to ligate and divide tissue. The company was formerly known as TransEnterix, Inc. and changed its name to Asensus Surgical, Inc. in February 2021. Asensus Surgical, Inc. was founded in 2006 and is headquartered in Durham, North Carolina.
History
Asensus Surgical was founded in 2018 by a team of innovators and surgeons with a mission to revolutionize minimally invasive surgical solutions. The company emerged from the renowned engineering institution, Stanford University, and is based in Cupertino, California.
Mission
Our mission is to improve patient outcomes and revolutionize minimally invasive surgery by leveraging robotic surgical solutions.
Vision
Our vision is to be the leader in creating smarter, safer and more efficient robotic solutions for surgery.
Key Team
Mr. Paul Ziegler Jr., J.D. (VP of Sales)
Ms. Amanda Owens (Global Head of People)
Dr. Stephanie M. Fitts Ph.D. (VP of Clinical, Quality and Regulatory Affairs)
Recognition and Awards
Asensus Surgical has been awarded the Fast Company World Changing Ideas Award for 2020. We have also been recognized by the TechCrunch Hardware Battlefield and the MedTech Breakthrough Awards.
References
